India’s Weight-Loss Drug Market Surges Sixfold Amid Rising Demand
India is experiencing a dramatic increase in the demand for weight-loss drugs, with the market growing sixfold in the past five years as more young professionals and individuals with diabetes seek pharmaceutical assistance with weight management.
Increasingly, doctors in urban centers are reporting consultations not solely from patients managing blood sugar, but from individuals seeking prescriptions for drugs like semaglutide and tirzepatide. A 23-year-old man recently approached Mumbai-based diabetologist Rahul Baxi concerned about weight gain after starting a demanding job, illustrating a trend of preventative use beyond medical necessity. “One of my gym friends is on [weight loss] jabs,” he reportedly said. Dr. Baxi cautioned against relying on medication without lifestyle changes, stating, “Stop, and the weight comes back. Keep going, and without exercise you’ll start losing muscle instead. These medicines aren’t a substitute for a proper diet or lifestyle change.”
The popularity of these GLP-1 drugs, originally developed for diabetes treatment, is fueled by their effectiveness, offering results previously unattainable with other methods. The market has jumped from $16 million in 2021 to nearly $100 million today, according to research firm Pharmarack. Novo Nordisk’s semaglutide brands, particularly Rybelsus, currently dominate the market, accounting for nearly two-thirds of sales since its 2022 launch, while Eli Lilly’s tirzepatide (Mounjaro) quickly became the second-bestselling branded drug by September. The rising rates of obesity and Type 2 diabetes in India – with over 77 million people affected by the latter – contribute to the growing demand, and the potential for cheaper generic versions following patent expirations in March could further expand access. You can learn more about the health challenges facing India at the World Health Organization India website.
However, concerns are mounting regarding misuse, the potential for side effects like nausea and pancreatitis, and the lack of medical supervision, with reports of prescriptions being issued by unqualified individuals and drugs being purchased on the black market. Federal minister Jitendra Singh has “advised caution” regarding the new drugs, and doctors warn that prolonged use without exercise can lead to muscle loss, exacerbating existing issues like sarcopenic obesity. As the Centers for Disease Control and Prevention explains, obesity is a complex health issue with far-reaching consequences. Mumbai-based bariatric surgeon Muffazal Lakhdawala emphasized that “Most don’t realise that obesity is a chronic, relapsing disease.”
Officials are monitoring the situation closely, and doctors are urging a focus on holistic approaches to weight management, including diet and exercise, rather than relying solely on pharmaceutical interventions.
